CellSync

CellSync Biosciences is a biotechnology company focused on gene delivery and cell engineering to improve treatments for cancer patients. Founded in 2023 by Dr. Dorsa Rad and Professor Majid E. Warkiani, the company is headquartered in Sydney, Australia. Dr. Rad serves as the CEO. The company is developing technology to efficiently engineer immune cells, aiming to make them more effective at fighting cancer. This approach is intended to be faster, safer, and more affordable than existing methods, with the goal of enhancing both the quality of care and the quality of life for individuals with cancer.

CellSync Biosciences operates in the HealthTech, Life Sciences, and Oncology sectors. The company has received investment from the accelerator Founders 10x and was a recipient of the UTS Techcelerator program award and a Sydney Vital Grant. As of early August 2024, CellSync has a pending patent for intracellular delivery. The company has also initiated collaborations with Key Opinion Leaders (KOLs) and has started manufacturing discussions with the UK-based company TTP.

Keywords: gene delivery, cell engineering, oncology, cancer treatment, immunotherapy, biotechnology, HealthTech, Life Sciences, immune cells, cell therapy, cancer research, intracellular delivery, Dorsa Rad, Majid E. Warkiani, Founders 10x, UTS Techcelerator, Sydney Vital Grant, TTP collaboration, preclinical development, therapeutic engineering